NovelBeam Technology

Executive Summary

NovelBeam Technology is a Beijing-based medical device company focused on advancing cancer radiotherapy through compact, cost-effective linear accelerator (LINAC) systems. Founded in 2016, the company aims to democratize access to precise radiation therapy by reducing the footprint and cost of traditional LINAC equipment, making it viable for smaller hospitals and clinics in China and emerging markets. Its proprietary technology emphasizes accuracy and efficiency, positioning it as a key player in the growing Chinese radiotherapy market, which is expanding due to rising cancer incidence and government initiatives to improve healthcare infrastructure. With a commercial-stage product portfolio, NovelBeam has established a foothold in China and is now seeking to expand internationally. The global radiotherapy market is projected to grow steadily, driven by technological innovations and increasing demand for non-invasive cancer treatments. NovelBeam’s value proposition lies in its ability to offer high-precision treatment at a fraction of the cost of conventional systems, addressing a critical gap in affordable oncology care. The company's compact design also enables easier installation and maintenance, reducing operational barriers. While competition from established players like Varian and Elekta is intense, NovelBeam’s cost advantage and localization in China provide a strategic edge. Near-term growth will depend on securing regulatory approvals for next-generation devices and building clinical evidence through partnerships with leading cancer centers.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for next-gen compact LINAC system70% success
• Q4 2026Strategic partnership with major hospital chain in China60% success
• Q1 2027CE marking submission for European market entry50% success